KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.95

Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.

Vlado Perkovic, Hernán Trimarchi, Vladimir Tesar, Richard Lafayette, Muh Geot Wong, Jonathan Barratt, Yusuke Suzuki, Adrian Liew, Hong Zhang, Kevin Carroll, Vivekanand Jha, Alejandra Quevedo, Seung Hyeok Han, Manuel Praga, Bobby Chacko, Manisha Sahay, Chee Kay Cheung, Laura Kooienga, Michael Walsh, Jing Xia, Cecile Fajardo, Lokesh Shah, Jeffrey Hafkin, Dana V Rizk, VISIONARY Trial Investigators Group

N Engl J Med 394(7) 635-646

PMID41211929
PMCID-
DOI10.1056/NEJMoa2512133
发表日期2025-11-10
入排依据:The trial is a randomized, Phase III study of a drug intervention in humans, but it is not an oncology trial (targets IgA nephropathy). Furthermore, the primary and key secondary endpoints (proteinuria reduction, eGFR slope) are not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or hazard ratio analysis.
PubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。
摘要

摘要

BACKGROUND: The cytokine A proliferation-inducing ligand (APRIL) is considered a key driver of the pathogenesis of IgA nephropathy. Sibeprenlimab, a humanized IgG2 monoclonal antibody, selectively binds to and inhibits APRIL. METHODS: In this phase 3, multicenter, double-blind, randomized, placebo-controlled trial, we assigned adults with biopsy-confirmed IgA nephropathy in a 1:1 ratio to receive either subcutaneous sibeprenlimab at a dose of 400 mg or placebo administered every 4 weeks for 100 weeks. The primary end point for this interim analysis was the 24-hour urinary protein-to-creatinine ratio at 9 months as compared with baseline. The key secondary end point, to be reported at trial completion, is the annualized slope of estimated glomerular filtration rate over 24 months. Other secondary end points included the change in the level of serum immunoglobulin and safety. Exploratory end points included the change in galactose-deficient IgA1 and APRIL concentrations, the spot 24-hour urinary protein-to-creatinine ratio, hematuria, and remission of proteinuria. RESULTS: A total of 510 patients underwent randomization - 259 to the sibeprenlimab group and 251 to the placebo group. The prespecified interim analysis included the first 320 patients (152 who received sibeprenlimab and 168 who received placebo) who had the opportunity to complete the 9-month evaluation of the 24-hour urinary protein-to-creatinine ratio. At 9 months, a significant reduction in 24-hour urinary protein-to-creatinine ratio was observed with sibeprenlimab (-50.2%) as compared with an increase with placebo (2.1%), corresponding to an adjusted geometric least-squares mean 24-hour urinary protein-to-creatinine ratio that was 51.2% (96.5% confidence interval [CI], 42.9 to 58.2) lower with sibeprenlimab than with placebo (P<0.001). The levels of APRIL and pathogenic galactose-deficient IgA1 at week 48 were reduced from baseline by 95.8% and 67.1%, respectively, with sibeprenlimab. The safety profile appeared to be similar with sibeprenlimab and placebo. No deaths were reported, and the incidence of serious adverse events that occurred during the treatment period was 3.5% with sibeprenlimab and 4.4% with placebo. CONCLUSIONS: Sibeprenlimab resulted in a significant reduction in proteinuria as compared with placebo in patients with IgA nephropathy. (Funded by Otsuka Pharmaceutical Development and Commercialization. VISIONARY ClinicalTrials.gov number, NCT05248646.).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。